Appendix 1

2008 Author Relationships With Industry and Other Entities (Relevant)—ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities

Committee MemberConsulting Fees/HonorariaSpeakers' BureauOwnership/Partnership/PrincipalResearch GrantsInstitutional or Other Financial Benefit
Andrew E. Epstein
  • Boston Scientific

  • CryoCath

  • Medtronic

  • Sanofi-Aventis

  • St. Jude

  • Boston Scientific

  • Medtronic

  • Reliant Pharmaceuticals

  • Sanofi-Aventis

  • St. Jude

None
  • Biotronik

  • Boston Scientific

  • C. R. Bard/Electrophysiology Division

  • Irving Biomedical

  • Medtronic

  • St. Jude

Electrophysiology fellowship support from:
  • Medtronic

  • St. Jude

John P. DiMarco
  • Boston Scientific

  • CV Therapeutics

  • Daiichi Sankyo

  • Medtronic

  • Novartis

  • Sanofi-Aventis

  • Solvay

  • St. Jude

NoneNone
  • Boston Scientific

  • CV Therapeutics

  • Medtronic

  • Sanofi-Aventis

  • St. Jude

None
Kenneth A. Ellenbogen
  • Ablation Frontiers

  • Atricure

  • Biosense Webster

  • Biotronik

  • Boston Scientific

  • Medtronic

  • Sorin/ELA

  • St. Jude

  • Reliant Pharmaceuticals

  • Sanofi-Aventis

None
  • Biosense Webster

  • Boston Scientific

  • Cameron Medical

  • Impulse Dynamics

  • Medtronic

  • St. Jude

None
N.A. Mark Estes III
  • Medtronic

  • Boston Scientific

  • Medtronic

  • St. Jude

NoneNoneNone
Roger A. Freedman
  • Boston Scientific

  • Medtronic

  • Sorin/ELA

  • St. Jude

  • Boston Scientific

  • St. Jude

  • St. Jude

  • Boston Scientific

  • Medtronic

  • St. Jude

University of Utah Division of Cardiology receives electrophysiology fellowship support grants from:
  • Boston Scientific

  • Medtronic

  • St. Jude

Leonard S. GettesNoneNoneNoneNoneNone
A. Marc Gillinov
  • AtriCure

  • Edwards

  • Medtronic

  • Guidant

  • St. Jude

  • Viacor

NoneNone
Gabriel GregoratosNoneNoneNoneNoneNone
Stephen C. Hammill
  • Biosense Webster

  • Boston Scientific

None
  • Medtronic

None
David L. Hayes
  • AI Semi

  • Blackwell/Futura

  • Boston Scientific

  • Medtronic

  • Sorin/ELA

  • St. Jude

NoneNone
  • Boston Scientific

  • Medtronic

  • St. Jude

  • Biotronik

  • Boston Scientific

  • Medtronic

  • Sorin/ELA

  • St. Jude

Mark A. Hlatky
  • Blue Cross/Blue Shield Technology Evaluation Center

NoneNoneNoneNone
L. Kristin Newby
  • AstraZeneca/Atherogenics

  • Biosite

  • CV Therapeutics

  • Johnson & Johnson

  • Novartis

  • Procter & Gamble

  • Roche Diagnostics

NoneNone
  • Adolor

  • American Heart Association

  • BG Medicine

  • Bristol-Myers Squibb/Sanofi

  • Inverness Medical

  • Medicure

  • Schering-Plough

None
Richard L. Page
  • Astellas

  • Berlex

  • Pfizer

  • Sanofi-Aventis

NoneNone
  • Procter & Gamble

  • Boston Scientific

  • Medtronic

  • St. Jude

Mark H. SchoenfeldNoneNoneNoneNoneNone
Michael J. SilkaNoneNoneNoneNoneNone
Lynne Warner Stevenson
  • Biosense Webster

  • Boston Scientific

  • CardioMEMS

  • Medtronic

  • Medtronic

  • Scios

NoneNone
  • Biosense Webster

  • Medtronic

None
Michael O. Sweeney
  • Medtronic

  • Boston Scientific

  • Medtronic

NoneNoneNone

This table represents the relationships of committee members with industry that were reported orally at the initial writing committee meeting and updated in conjunction with all meetings and conference calls of the writing committee during the document development process (last revision, January 16, 2008). It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted.

  • Recused from voting on guideline recommendations.

  • Indicates significant-level relationship (more than $10,000).

  • Indicates spousal relationship.